Transcript Challenges in the Fight against TB in Africa

Community Representative Update
Albert S. Makone
Introduction

Only 132 000 people with drug-resistant TB (DRTB) diagnosed (out of an estimated 580 000 new
DR TB cases), and only 50% of those that
started the life-saving DR-TB regimens are
cured.
WHO Global TB Report 2016
2
Key Activities

Enhance the understanding of Civil Society and key affected
communities about the NDWG mandate


Increasing NDWG membership




Share with Civil Society and key affected communities about the NDWG
drug pipeline
Distributing the call for membership in different regional networks
Building movement led by patients- including empowering and
strengthening the voices of the affected community on TB
research and new tools
Advocating to make TB services free and accessible
Participate in DR-TB STAT Taskforce to accelerate access to new
drugs for MDR-TB
3
Key Issues
Engagement of TB affected communities at national,
regional and global level remains superficial and
limited.
 The global battle to end TB will not be possible
without the proper involvement of its most
important stakeholder, the people and communities
affected by this disease.

4
Moving Forward
Strengthen national and regional networks and
coalitions of TB affected communities
 Strengthen linkage with existing national, regional
and global organizations and partners
 To strengthen the capacity of TB affected community
to be effectively engaged in all processes at all levels
 To advocate for more resources and new tools for TB
control

5
Moving Forward
We need to do things differently!!!
 Over 75% of TB money comes from Global Fund in
Africa
 Increase Domestic financing for health
 Increase investment in TB R&D

6

Thank you


Tatenda
Ngiyabonga
7
#StepUpforTB
DIAGNOSTICS
 No out-of-pocket costs
 Rapid molecular tests
 Second-line drug susceptibility tests
MODELS OF CARE
 PHC treatment, DRTB at district/below
 Hospitalisation not required
 Immediate ART for PLWHA
498DAYS
DRUG REGULATION
 Quality-assured TB drugs
 Prescriptions required
 Accelerated registration
DS-TB TREATMENT
 Daily fixed-dose combinations
 WHO treatment guidance
 Screening contacts and IPT
DR-TB TREATMENT
 WHO DR-TB guidance
 Essential Medicines List (EML)
 Import waivers until registration
DR-TB STAT Task Force
• Formed in April 2015 in response to the “Call to Action” to
accelerate access to new drugs for MDR-TB*
• Officially adopted as a Global DR-TB Initiative task force in
July 2015
• Multiagency participation
• Collects information from National TB Programs each
month on the use of BDQ and DLM
• Provides technical assistance and support for countries to
overcome barriers to new drug introduction
• Data current to 1 September 2016
• See more at www.drtb-stat.org
*http://www.msfaccess.org/content/call-action-accelerate-access-dr-tb-drugs
Bedaquiline progress
• 5234 patients enrolled as of 1 September 2016 (60% in South Africa, 20% in
Russia)
• 4663 orders from GDF
• As of 1 May 2016, BDQ has been registered with 12 regulatory authorities
(Armenia, the European Union, India, Macau, Peru, Philippines, Russia, South
Africa, South Korea, Taiwan, Turkmenistan, the United States, and Uzbekistan)
• Dossiers have been submitted to an additional 17 countries
6000
5000
4000
3000
BDQ
2000
1000
0
Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16
Delamanid progress
• 366 patients on DLM, all in MSF or PIH sites
• 1018 orders from GDF
• DLM registered in Japan, South Korea, Hong Kong, the European Union,
Turkey, and the Philippines; not registered in any MDR-TB high-burden
countries
• Dossiers have been submitted for registration in the Philippines, Indonesia,
Turkey and Vietnam
400
350
300
250
200
150
100
50
0
DLM